QSC ships research-grade orforglipron to Alberta, Canada. Orforglipron (LY3502970) is an oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly — the first small-molecule GLP-1R agonist class to demonstrate clinically meaningful weight loss (Phase 2: up to 14.7% at 36 weeks) without requiring injection or food restrictions.
Every QSC orforglipron batch is verified at ≥99% HPLC purity with mass spectrometry molecular confirmation. Each batch has a Janoshik certificate of analysis, independently verifiable at verify.janoshik.com. All products sold strictly for in vitro laboratory research only — not for human or veterinary use.
Shipping to Alberta: International Shipping · 5-10 business days · All orders include tracking · Research-grade peptides and compounds shipped discreetly.
Research Use Only: Orforglipron is sold by QSC for in vitro laboratory research only. Not for human use. Researchers are responsible for compliance with local regulations in Alberta.
